0
Abstract: Poster Presentations |

CURB-65 PNEUMONIA SEVERITY INDEX AND APACHE II SCORES TO ASSESS MORTALITY RISK IN COMMUNITY-ACQUIRED PNEUMONIA PATIENTS FROM PROWESS FREE TO VIEW

Guy Richards, MB, BCh*; Howard Levy, MB, BCh; Pierre-Francois Laterre, MD; Charles Feldman, MB, PhD; Becky M. Bates, MS; Rebecca L. Qualy, MS
Author and Funding Information

University of Witwatersrand, Johannesburg, South Africa


Chest


Chest. 2007;132(4_MeetingAbstracts):559. doi:10.1378/chest.132.4_MeetingAbstracts.559
Text Size: A A A
Published online

Abstract

PURPOSE: Patients with community-acquired pneumonia (CAP) comprised 35.6% of the PROWESS study and 33.1% of the placebo arm. We investigated the use of CURB-65, the Pneumonia Severity Index (PSI) and APACHE II prediction scores to identify the CAP population from the PROWESS placebo arm at the greatest mortality risk.

METHODS: Patients were classified as having CAP if the lung was the primary infection site and the patient originated from home. The abilities of CURB-65, PSI and APACHE II scores to determine 28-day and in-hospital mortality were compared using receiver operator characteristic (ROC) curves and the associated areas under the curve.

RESULTS: PROWESS enrolled 278 CAP patients in the placebo arm. The areas under the ROC curves for PSI =5, CURB-65 ≥3, and APACHE II ≥25 for predicting 28-day (c =0.65, 0.66, 0.64, respectively) and in-hospital mortality (c =0.65, 0.65, 0.64, respectively) were not statistically different from each other. The 28-day mortality of patients with a PSI score =5, CURB-65 ≥3 and APACHE II ≥25 was 41.6%, 37.9%, and 43.5% respectively.

CONCLUSION: Despite early diagnosis and appropriate antibiotic therapy, conventionally treated CAP with PSI scores =5, CURB-65 scores ≥3, or APACHE II ≥25 has an unacceptably high mortality. In this study, PSI, CURB-65 and APACHE II scoring systems perform similarly in predicting 28-day and in-hospital mortality.

CLINICAL IMPLICATIONS: The PSI and APACHE II are cumbersome and time-consuming to perform while CURB-65 is simple and rapid and may provide more efficient risk stratification in patients with severe CAP. CTR#1678.

DISCLOSURE: Guy Richards, No Product/Research Disclosure Information; Shareholder I hold shares of stock in Eli Lilly and Company; Employee I am a full-time employee of Eli Lilly and Company

Wednesday, October 24, 2007

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543